Free Submission Public Relations & NewsPR-inside.com
 
DeutschEnglish

Get the latest news
with our RSS feed
rss feed
Add to My Yahoo!
More information
Business
Jazz Pharmaceuticals Inc - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis

Jazz Pharmaceuticals Inc - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis - www.companiesandmarkets.com adds new report


Print article Print article
Refer this article Refer to a friend
© companiesandmarkets.com
2008-07-17 11:25:20 - Jazz Pharmaceuticals Inc - Corporate and Strategic Assessment Report – Company Strategy, SWOT Analysis - a new market research report on www.companiesandmarkets.com

www.companiesandmarkets.com/Summary-Company-Profile/Jazz-Pharmac ..

Introduction

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. The company´s product portfolio includes three marketed products, namely, Xyrem, Luvox CR and Antizol.



Scope

Contains corporate strategy, value chain presence and SWOT Analysis
Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors
Includes information

on suppliers/ partners, shareholding structure and key employees with biographies


Highlights

The company´s product portfolio include Xyrem, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Luvox CR, for the treatment of obsessive compulsive disorder social anxiety disorder; and Antizol, for the treatment of ethylene glycol and methanol poisoning.



Its product pipeline comprises JZP-6, the company´s lead candidate undergoing Phase III trials for the treatment of fibromyalgia syndrome and Phase II programs in recurrent acute repetitive seizures (JZP-8), epilepsy bipolar disorder (JZP-4) and restless legs syndrome (JZP-7).



Jazz Pharmaceuticals´ major contributor to the total sales growth out to 2010 will be the revenues from the product sales of Luvox CR. Luvox CR product revenues are expected to increase from $42 million in 2008 (year of launch) to $166 million in 2010.



Reasons to Purchase

Access all the important information and analysis on the company in a single report
Understand company´s strengths, weaknesses, opportunities and threats along with business strategy and value chain
Gain access to company´s adjusted five year financial data along with key ratios and market capitalization


www.companiesandmarkets.com/Summary-Company-Profile/Jazz-Pharmac ..


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Terms & Conditions | Privacy | About us | Contact PR-inside.com